Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line

Prostate

Volumn 30, Issue 4, 1997, Pages 232-242

  Troyer, John K ^a,b   Beckett, Mary Lou ^a,b   Wright Jr , George L ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Sentara Cancer Resource Centers   (United States)

Author keywords

biomarker; cancer; PSMA; tumor; tumor antigen

Indexed keywords

EPITOPE; GLYCOPROTEIN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL FRACTIONATION; CELL MEMBRANE; CELLULAR DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOPEROXIDASE STAINING; MITOCHONDRION; NECROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN LOCALIZATION;

EID: 0030940108     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970301)30:4<232::AID-PROS2>3.0.CO;2-N     Document Type: Article

References (26)

1. Wingo PA, Tong T, Bolden S: Cancer statistics. CA 45: 8-30, 1995.
2. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anti-cancer Res 7:927-936, 1987.
3. Wright GL Jr, Haley C, Beckett ML, Schellhammer PF: Expression of prostate specific membrane antigen (PSMA) in normal, benign, and malignant prostate tissues. Urol Oncol 1:18-28, 1995.
4. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152:1490-1495, 1994.
5. 111indium-labeled monoclonal antibody CYT-356. J Urol 152:1952-1955, 1994.
6. Axelrod HRR, Gilman SC, D'Aleo CJ, Petrylack D, Reuter V, Gulfo JV, Saad A, Cordon-Cardo C, Scher HRI: Preclinical results and human immunohistochemical studies with 90Y-CYT-356: A new prostate cancer therapeutic agent. J Urol 147:361A (Abstract 596), 1992.
7. Troyer JK, Feng Q, Beckett ML, Wright GL Jr: Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate specific membrane antigen. Urol Oncol 1:29-37, 1995.
8. Shaulsky G, Ben-Ze'ev A, Rotter V: Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5:1707-1711, 1990.
9. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: Residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53:4701-4714, 1993.
10. Akao Y, Otsuki Y, Kataoka S, Ito Y, Tsujimoto Y: Multiple subcellular localization of bcl-2: Detection in nuclear outer membrane, endoplasmic reticulum membrane, and mitochondrial membranes. Cancer Res 54: 2468-2471, 1994.
11. Danscher G, Norgaard JOR: Light microscopic visualization of colloidal gold on resin-embedded tissue. J Histochem Cytochem 31:1394-1398, 1983.
12. Simsin JAV, Fenters R, Chao J: Electron microscopic immunostaining of kallikrein in rat submandibular glands. J Histochem Cytochem 31:301-306, 1983.
13. Song GX, Lin CT, Wu JY, Lam KW, Li CY, Yam LT: Immunoelectron microscopic demonstration of prostatic acid phosphatase in human hyperplastic prostate. Prostate 7:63-71, 1985.
14. Lazarus GM, Henrich JP, Kelly WG, Schmitz SA, Castora FJ: Purification and characterization of a type I DNA topoisomerase from calf thymus mitochondria. Biochemistry 26:6196-6203, 1987.
15. Karlsson GB, Platt FM: Analysis and isolation of human transferrin receptor using the OKT-9 monoclonal antibody covalently crosslinked to magnetic beads. Anal Biochem 199:219-222, 1991.
16. Hicke L, Schekman R: Molecular machinery required for protein transport from the endoplasmic reticulum to the Golgi complex. Bioassays 12:253-258, 1990.
17. DePotter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Roels H: The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44:969-974, 1989.
18. Wright GL Jr, Grob M, Huang CL, Troyer JK, Adam BL, Cazares L, Schellhammer PF: Comparison of HER2-neu in prostate and breast carcinomas. Proc Am Assoc Cancer Res 36:644 (Abstract 3837), 1995.
19. Wright GL Jr, Grob M, Troyer JK, Adam BL, Cazares L, Schellhammer PF: HER2-neu expression in prostate carcinomas is not the same as that found in breast carcinomas. J Urol 153:271A (Abstract 170), 1995.
20. Liao X, Butow RA: RTG1 and RTG2: Two yeast genes required for a novel path of communication from mitochondria to the nucleus. Cell 72:61-71, 1993.
21. Vandewoude MF, Buyssens N: Effect of aging and malnutrition on rat myocardium. I. The myocyte. Virchows Arch [A] 421:179-188, 1992.
22. Thie M, Schlumberger W, Semich R, Rauterberg J, Robenek HR: Aortic smooth muscle cells in collagen lattice culture: Effects on ultrastructure, proliferation and collagen synthesis. Eur J Cell Biol 55:295-304, 1991.
23. Isaacs JT, Furuya Y, Berges R: The role of androgen in the regulation of programmed cell death/apotosis in normal and malignant prostatic tissue. Semin Cancer Biol 5:391-400, 1994.
24. Isaacs JT: Role of androgens in prostatic cancer. Vitam Horm 49:433-502, 1994.
25. Abdel-Nabi H, Wright GL Jr, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mitchell E, Purnell G, Harwood SJ: Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 10:45-54, 1992.
26. Hakim AA, Grand NG: Micro-necrotic foci in regression of a murine calvarium transplantable tumor. 3. Histological characteristics of the micro-necrotic foci. Neoplasma 27:459-471, 1980.